Physician profile
Brant D Morrow
NPI 1306342530
$918.05
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $896 · 2022: $21.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.66 | 2021 | |
| Glaxosmithkline, LLC. | $135.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.13 | 2021 | |
| Astellas Pharma US INC | $87.87 | 2021-2022 | |
| Novo Nordisk INC | $78.48 | 2021 | |
| Sunovion Pharmaceuticals INC. | $58.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $43.17 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.81 | 2021 | |
| Lilly USA, LLC | $41.52 | 2021 | |
| Sanofi-Aventis U.S. LLC | $37.36 | 2021 | |
| Axonics, INC. | $17.71 | 2021 | |
| Eisai INC. | $15.18 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2021 | |
| Vistapharm, INC. | $13.20 | 2021 | |
| Abbott Laboratories | $11.84 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brant Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.